Եվրոպական Միություն - լատվիերեն - EMA (European Medicines Agency)

novartis europharm limited - eltrombopags - purpura, trombocitopēnija, idiopātija - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 un 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 un 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.

Եվրոպական Միություն - լատվիերեն - EMA (European Medicines Agency)

gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.

Եվրոպական Միություն - լատվիերեն - EMA (European Medicines Agency)

gilead sciences ireland uc - sofosbuvīrs - c hepatīts, hronisks - pretvīrusu līdzekļi sistēmiskai lietošanai - sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adult and paediatric patients aged 3 years and above (see sections 4. 2, 4. 4 un 5. hepatīta c vīrusa (hcv) genotipa konkrētu darbību, skatīt 4. 4 un 5. sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adults and paediatric patients aged 3 years and above (see sections 4. 2, 4. 4 un 5. hepatīta c vīrusa (hcv) genotipa konkrētu darbību, skatīt 4. 4 un 5.

Եվրոպական Միություն - լատվիերեն - EMA (European Medicines Agency)

gilead sciences ireland uc - emtricitabine, tenofovir disoproxil fumarate - hiv infekcijas - pretvīrusu līdzekļi sistēmiskai lietošanai - treatment of hiv-1 infection: , truvada is indicated in antiretroviral combination therapy for the treatment of hiv-1 infected adults. , truvada ir arī norādīts par attieksmi pret hiv-1 inficētiem pusaudžiem, ar nrti pretestības vai toksicitātes rādītājs, kas liedz izmantot pirmās līnijas pārstāvji, vecumā no 12 līdz 18 gadiem. , pre-exposure prophylaxis (prep): , truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired hiv-1 infection in adults at high risk.

Եվրոպական Միություն - լատվիերեն - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cistiskā fibroze - other respiratory system products - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Եվրոպական Միություն - լատվիերեն - EMA (European Medicines Agency)

pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.

Եվրոպական Միություն - լատվիերեն - EMA (European Medicines Agency)

laboratorios farmacéuticos rovi, s.a. - risperidons - Šizofrēnija - psihoterapija - treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.

Եվրոպական Միություն - լատվիերեն - EMA (European Medicines Agency)

viatris limited - dapagliflozīns - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - cukura diabēts - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 un 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Եվրոպական Միություն - լատվիերեն - EMA (European Medicines Agency)

accord healthcare s.l.u. - dabigatrāna eteksilāta mesilāts - venous thromboembolism; arthroplasty, replacement - antitrombotiskie līdzekļi - prevention of venous thromboembolic events.

Եվրոպական Միություն - լատվիերեն - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imūnsupresanti - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 un 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.